File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients - A cost analysis

TitleAtypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients - A cost analysis
Authors
KeywordsAmisulpride
Cost analysis
Olanzapine
Quetiapine
Risperidone
Issue Date2007
Citation
International Journal Of Clinical Pharmacology And Therapeutics, 2007, v. 45 n. 5, p. 264-270 How to Cite?
AbstractObiective: To evaluate the direct medical cost of atypical antipsychotic therapy for schizophrenia among Hong Kong Chinese patients and to identify factors affecting the cost of treatment. Methods: In this retrospective database analysis, patient data were retrieved from three Hong Kong public hospitals. Patients aged ≥ 18 years who received an initial prescription for olanzapine, risperidone, quetiapme or amisulpride between April 1 and September 30, 2003; and had an ICD-10-coded diagnosis of schizophrenia were included. Patient data were collected for a maximum duration of 1 year before and after treatment initiation. Primary outcome measures were the schizophrenia-related direct medical costs. Demographic and clinical factors were analyzed by multiple regression analysis to identify influential factors for the cost of atypical antipsychotic therapy. Results: A total of 325 patient records were reviewed and 82 patients were included in the analysis. Cost per patient per month for clinic visits (US$ 67 ± 41 versus US$ 78 ± 41), medications (US$ 8 ± 12 versus US$ 97 ± 83), and the total cost per patient per month (US$ 314 ± 898 versus US$ 431 ± 914) increased significantly after treatment initiation (US$ 1 = HK$ 7.8). Previous duration of hospitalization (RR = 1.00, 95% CI= 1.00 - 1.01), history of substance abuse (RR = 1.26, 95% CI = 1.05 - 1.52) and use of depot antipsychotics (RR = 1.22, 95% CI = 1.05 - 1.42) were associated with higher cost of atypical antipsychotic therapy. Conclusion: The total direct medical cost increased significantly after initiation of atypical antipsychotic therapy in a cohort of Chinese patients with schizophrenia. History of drug abuse, use of depot antipsychotics and prior duration of hospitalization were positive predictors of cost of therapy. ©2007 Dustri-Verlag Dr. K. Feistle.
Persistent Identifierhttp://hdl.handle.net/10722/84234
ISSN
2015 Impact Factor: 1.129
2015 SCImago Journal Rankings: 0.400
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLaw, WLen_HK
dc.contributor.authorHui, HYen_HK
dc.contributor.authorYoung, WMen_HK
dc.contributor.authorYou, JHSen_HK
dc.date.accessioned2010-09-06T08:50:32Z-
dc.date.available2010-09-06T08:50:32Z-
dc.date.issued2007en_HK
dc.identifier.citationInternational Journal Of Clinical Pharmacology And Therapeutics, 2007, v. 45 n. 5, p. 264-270en_HK
dc.identifier.issn0946-1965en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84234-
dc.description.abstractObiective: To evaluate the direct medical cost of atypical antipsychotic therapy for schizophrenia among Hong Kong Chinese patients and to identify factors affecting the cost of treatment. Methods: In this retrospective database analysis, patient data were retrieved from three Hong Kong public hospitals. Patients aged ≥ 18 years who received an initial prescription for olanzapine, risperidone, quetiapme or amisulpride between April 1 and September 30, 2003; and had an ICD-10-coded diagnosis of schizophrenia were included. Patient data were collected for a maximum duration of 1 year before and after treatment initiation. Primary outcome measures were the schizophrenia-related direct medical costs. Demographic and clinical factors were analyzed by multiple regression analysis to identify influential factors for the cost of atypical antipsychotic therapy. Results: A total of 325 patient records were reviewed and 82 patients were included in the analysis. Cost per patient per month for clinic visits (US$ 67 ± 41 versus US$ 78 ± 41), medications (US$ 8 ± 12 versus US$ 97 ± 83), and the total cost per patient per month (US$ 314 ± 898 versus US$ 431 ± 914) increased significantly after treatment initiation (US$ 1 = HK$ 7.8). Previous duration of hospitalization (RR = 1.00, 95% CI= 1.00 - 1.01), history of substance abuse (RR = 1.26, 95% CI = 1.05 - 1.52) and use of depot antipsychotics (RR = 1.22, 95% CI = 1.05 - 1.42) were associated with higher cost of atypical antipsychotic therapy. Conclusion: The total direct medical cost increased significantly after initiation of atypical antipsychotic therapy in a cohort of Chinese patients with schizophrenia. History of drug abuse, use of depot antipsychotics and prior duration of hospitalization were positive predictors of cost of therapy. ©2007 Dustri-Verlag Dr. K. Feistle.en_HK
dc.languageengen_HK
dc.relation.ispartofInternational Journal of Clinical Pharmacology and Therapeuticsen_HK
dc.subjectAmisulprideen_HK
dc.subjectCost analysisen_HK
dc.subjectOlanzapineen_HK
dc.subjectQuetiapineen_HK
dc.subjectRisperidoneen_HK
dc.titleAtypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients - A cost analysisen_HK
dc.typeArticleen_HK
dc.identifier.emailLaw, WL: lawwl@hkucc.hku.hken_HK
dc.identifier.authorityLaw, WL=rp00436en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid17542348en_HK
dc.identifier.scopuseid_2-s2.0-34248388586en_HK
dc.identifier.hkuros141090en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34248388586&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume45en_HK
dc.identifier.issue5en_HK
dc.identifier.spage264en_HK
dc.identifier.epage270en_HK
dc.identifier.isiWOS:000246817900003-
dc.identifier.scopusauthoridLaw, WL=7103147867en_HK
dc.identifier.scopusauthoridHui, HY=16307006100en_HK
dc.identifier.scopusauthoridYoung, WM=16308466700en_HK
dc.identifier.scopusauthoridYou, JHS=7201683649en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats